Product Description
Asoprisnil is a novel selective steroid receptor modulator that shows unique pharmacodynamic effects in animal models and humans. Asoprisnil, its major metabolite J912, and structurally related compounds represent a new class of progesterone receptor (PR) ligands that exhibit partial agonist and antagonist activities in vivo. Asoprisnil demonstrates a high degree of receptor and tissue selectivity, with high-binding affinity for PR, moderate affinity for glucocorticoid receptor (GR), low affinity for androgen receptor (AR), and no binding affinity for estrogen or mineralocorticoid receptors. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/14667995/)
Mechanisms of Action: PR Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Abbott Laboratories
Company Location: Eastern America
Company CEO: Robert B. Ford
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Leiomyoma|Menorrhagia|Metrorrhagia|Myofibroma
Phase 2: Endometriosis|Myofibroma|Menorrhagia|Leiomyoma|Menopause
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00156182 |
M01-275 | P2 |
Completed |
Myofibroma|Leiomyoma |
2001-12-01 |
2019-03-21 |
Treatments |
|
NCT00150644 |
C02-003 | P2 |
Completed |
Myofibroma|Leiomyoma |
2005-05-01 |
2019-03-21 |
Treatments |
|
NCT00160420 |
M02-408 | P2 |
Completed |
Endometriosis |
2004-07-01 |
2019-03-21 |
Treatments |
|
NCT00160433 |
M01-398 | P2 |
Completed |
Endometriosis |
2003-06-01 |
2019-03-21 |
||
NCT00152295 |
M01-280 | P2 |
Completed |
Menopause |
2001-12-01 |
2019-03-21 |
Treatments |
|
NCT00152282 |
M00-198 | P2 |
Completed |
Menopause |
2001-08-01 |
2019-03-21 |
Treatments |
|
NCT00160446 |
M99-110 | P2 |
Completed |
Endometriosis |
2001-07-01 |
2019-03-21 |
Treatments |
|
NCT00160459 |
M99-144 | P2 |
Completed |
Myofibroma|Leiomyoma |
2001-07-01 |
2019-03-21 |
Treatments |
|
NCT00288691 |
NCT00288691 | P2 |
Completed |
Menorrhagia |
None |
2019-03-21 |
Treatments |
|
NCT00156156 |
A-FB04-078 | P3 |
Completed |
Menorrhagia|Myofibroma|Metrorrhagia|Leiomyoma |
2007-02-01 |
2019-03-21 |
||
NCT00156195 |
M01-391 | P3 |
Completed |
Menorrhagia|Metrorrhagia|Myofibroma|Leiomyoma |
2007-01-01 |
2019-03-21 |
Treatments |
|
NCT00156208 |
C03-062 | P3 |
Completed |
Menorrhagia|Leiomyoma|Metrorrhagia|Myofibroma |
2006-12-01 |
2019-03-21 |
Treatments |
|
NCT00152256 |
C02-037 | P3 |
Completed |
Myofibroma|Metrorrhagia|Leiomyoma|Menorrhagia |
2005-02-01 |
2019-03-21 |
Treatments |
|
NCT00152269 |
J867 | P3 |
Completed |
Menorrhagia|Myofibroma|Leiomyoma|Metrorrhagia |
2005-01-01 |
2019-03-21 |
Treatments |
|
NCT00160381 |
M01-394 | P3 |
Completed |
Menorrhagia|Leiomyoma|Myofibroma|Metrorrhagia |
2005-01-01 |
2019-03-21 |
Treatments |